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c-Src: proto-oncogene tyrosine-protein kinase Src 32 
ERK1/2: extracellular signal–regulated kinase 1/2 33 
GBM: glioblastoma 34 
GSK-3: glycogen synthase kinase-3 35 
MOI: Multiplicity of infection 36 
MSK1/2: Mitogen- and Stress-activated protein Kinases 1 and 2 37 
mpi: minutes post infection 38 
hpi: hours post infection 39 
p38 MAPK: p38 mitogen-activated protein kinase 40 
PKA: Protein kinase A 41 
PKC: Protein kinase C 42 
PP1: serine/threonine-protein phosphatase 1 43 
PP2A: serine/threonine-protein phosphatase 2A  44 
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Abstract  74 
 75 
Adenovirus Delta-24-RGD has shown a remarkable efficacy in a phase I clinical trial for 76 
glioblastoma. Delta-24-RGD induces autophagy in glioma cells, however, the molecular 77 
derangements associated with Delta-24-RGD infection remains poorly understood. Here, 78 
proteomics was applied to characterize the glioma metabolic disturbances soon after 79 
Delta-24-RGD internalization and late in infection. Minutes post-infection, a rapid 80 
survival reprogramming of glioma cells was evidenced by an early c-Jun activation and 81 
a time-dependent dephosphorylation of multiple survival kinases. At 48 hours post-82 
infection (hpi), a severe intracellular proteostasis impairment was characterized, detecting 83 
differentially expressed proteins related to mRNA splicing, cytoskeletal organization, 84 
oxidative response, and inflammation. Specific kinase-regulated protein interactomes for 85 
Delta-24-RGD-modulated proteome revealed interferences with the activation dynamics 86 
of protein kinases C and A (PKC, PKA), tyrosine-protein kinase Src (c-Src), glycogen 87 
synthase kinase-3 (GSK-3) as well as serine/threonine-protein phosphatases 1 and 2A 88 
(PP1, PP2A) at 48hpi, in parallel with adenoviral protein overproduction. Moreover, the 89 
late activation of the nuclear factor kappa B (NF-κB) correlates with the extracellular 90 
increment of specific cytokines involved in migration, and activation of different 91 
inflammatory cells. Taken together, our integrative analysis provides further insights into 92 
the effects triggered by Delta-24-RGD in the modulation of tumor suppression and 93 
immune response against glioma. 94 
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1. Introduction 100 
DNX-2401 (Delta-24-RGD) is an oncolytic adenovirus that replicates selectively in 101 
retinoblastoma (Rb) pathway deficient cells and infects tumor cells efficiently (1-3). In 102 
general, results from pre-clinical and clinical studies have revealed that the adenovirus 103 
Delta-24-RGD is an attractive therapeutic agent for malignant gliomas (1, 4-7), 104 
demonstrating favorable toxicity profile and remarkable clinical efficacy (8). Indeed, 105 
novel clinical trials in combination with specific immunomodulators are currently active 106 
(Clinical-Trials.gov identifiers NCT02197169, and NCT02798406).  107 
It is well-known that the mechanism of oncolytic Delta-24-RGD-mediated tumor 108 
suppression involves adenovirus-induced activation of the autophagic machinery in 109 
glioma cells (9). We consider that understanding the proteostatic changes associated with 110 
the viral cycle of Delta-24-RGD, will provide new avenues to enhance the capability of 111 
viral release, and, as a result, to elicit a more therapeutic effect. Using quantitative 112 
extracellular and intracellular proteomics workflows, physical and functional interaction 113 
data, and biochemical approaches, we have partially characterized the missing links in 114 
the biochemical understanding of the signaling pathways impaired during the initial phase 115 
of attachment and internalization of viral particles as well as during the autophagic phase 116 
of Delta-24-RGD infection (10-13). More than 200 differential proteins were detected in 117 
Delta-24-RGD-infected glioma cells, pinpointing protein interaction networks, specific 118 
pathways, and potential novel therapeutic targets. In addition, a specific increase in 119 
specific cytokine subsets was detected by extracellular cytokine profiling of glioma-120 
infected cells, supporting the notion that Delta-24-RGD modulates pathways related to 121 
migration, and activation of different inflammatory cells.  122 
 123 
 124 
2 Materials and methods 125 
2.1 Materials 126 
The following reagents and materials were used: anti-GAPDH (Calbiochem), anti-PKC-127 
Pan, anti-pPKC-pan (T514), anti-pAkt (Ser473), anti-Akt, anti-cJUN, anti-phospho cJUN 128 
(S73), anti-NF-κB p65, anti-NF-κB phospho-p65 (S536), anti-IκB-alpha, anti-MEK, anti-129 
pMEK (S217/221), anti-PKAc alpha, anti-pPKAc (T197), anti-GSK-3α/β, anti-pGSK-130 
3α/β (S21/9) (Cell Signaling), anti-PP1, anti-c-src, anti-p-c-src (Y419), anti-E1A protein 131 
(Santa Cruz Biotechnology), anti-phospho PPP1A (T320), anti-PP2Aα/β (Abcam), and 132 
anti-fiber protein (Neomarkers). Electrophoresis reagents were purchased from Bio-rad 133 
and trypsin from Promega. 134 
2.2 Virus production, culture and treatment of malignant glioma cells.  135 
The generation of Delta-24-RGD vector has been previously described (1, 3). U87 MG 136 
glioma cells (ATCC: HTB-14) were cultured in DMEM/F12-GlutaMAX (Gibco 137 
10565018) supplemented with 10% FBS, and 1% penicillin/streptomycin. 2.5x106 U87 138 
cells were infected with Delta-24-RGD at multiplicity of infection (MOI) of 25. After 139 
incubation for 30 minutes with DMEM/F12 1% penicillin/streptomycin at 37 °C, the 140 
double of the volume of DMEM/F12-GlutaMAX (Gibco 10565018) supplemented with 141 
10% FBS and 1% penicillin and streptomycin was added to the previous media. Cells 142 
were incubated under the same conditions during the indicated periods of time (24 and 143 
48hpi). 144 
2.3 Mass-spectrometry based-proteomics 145 
After the indicated periods of time, the media was removed and the cells were washed 146 
with 1X cold PBS. The cellular pellets were resuspended in lysis buffer (7M urea, 2M 147 
thiourea, 50mM DTT) and let on ice for 30 minutes, spinning and vortexing each 10 148 
minutes. After a sonication step, the lysate was centrifuged for 60 minutes at 20000xg at 149 
15°C. Protein concentration of the supernatants was measured with the Bradford assay 150 
kit (Bio-rad). Total cell extracts from Mock-infected, and U87-infected cells (48hpi) were 151 
diluted in Laemmli sample buffer and loaded into a 1 mm thick polyacrylamide gel with 152 
a 4% stacking gel casted over a 12.5% resolving gel. The run was stopped as soon as the 153 
front entered 3 mm into the resolving gel so that the whole proteome became concentrated 154 
in the stacking/resolving gel interface. Bands were stained with Coomassie Brilliant Blue 155 
and excised from the gel. Protein enzymatic cleavage (15ug) was carried out with trypsin 156 
(Promega; 1:20, w/w) at 37°C for 16 h. Purification and concentration of peptides was 157 
performed using C18 Zip Tip Solid Phase Extraction (Millipore). Peptides mixtures were 158 
separated by reverse phase chromatography as previously described (26). The column 159 
gradient was developed in a 240 min two step gradient from 5% B to 25% B in 210 min 160 
and 25%B to 40% B in 30 min. Column was equilibrated in 95% B for 9 min and 5% B 161 
for 14 min. During all processes, precolumn was in line with column and flow maintained 162 
all along the gradient at 300 nl/min. Eluting peptides from the column were analyzed 163 
using a Sciex 5600 Triple-TOF system. Information data acquisition was acquired upon 164 
a survey scan performed in a mass range from 350 m/z up to 1250 m/z in a scan time of 165 
250 ms. Top 25-35 peaks were selected for fragmentation. Product ions were scanned in 166 
a mass range from 230 m/z up to 1500 m/z and excluded for further fragmentation during 167 
15 s. The MS/MS data acquisition was performed using Analyst 1.7.1 (Sciex) and spectra 168 
files were processed through Protein Pilot Software (v.5.0.1-Sciex) using Paragon™ 169 
algorithm (v.5.0.1) for database search, Progroup™ for data grouping, and searched 170 
against the concatenated target-decoy UniProt proteome reference database (Human 171 
database Proteome ID: UP000005640, 70902 proteins, December 2015 plus adenovirus 172 
HAv5 database UP000004992, 31 proteins, September 2016). False discovery rate was 173 
performed using a non-lineal fitting method and displayed results were those reporting a 174 
1% Global false discovery rate or better. The mass spectrometry proteomics data have 175 
been deposited to the ProteomeXchange Consortium 176 
(http://proteomecentral.proteomexchange.org) (55) via the PRIDE partner repository 177 
with the data set identifier PXD010256. 178 
(For reviewers, Username: reviewer37737@ebi.ac.uk; Password: IVLEQLmD) 179 
2.4 Data analysis 180 
The peptide quantification was performed using the Progenesis LC−MS software (ver. 181 
2.0.5556.29015, Nonlinear Dynamics). Using the accurate mass measurements from full 182 
survey scans in the TOF detector and the observed retention times, runs were aligned to 183 
compensate for between-run variations in our nanoLC separation system. To this end, all 184 
runs were aligned to a reference run automatically chosen by the software, and a master 185 
list of features considering m/z values and retention times was generated. The quality of 186 
these alignments was manually supervised with the help of quality scores provided by the 187 
software. The peptide identifications were exported from Protein Pilot software and 188 
imported in Progenesis LC− MS software where they were matched to the respective 189 
features. Output data files were managed for subsequent statistical analyses and 190 
representation. Proteins identified by site (identification based only on a modification), 191 
reverse proteins (identified by decoy database) and potential contaminants were filtered 192 
out. Proteins quantified with at least two unique peptides, a T-test p-value lower than 193 
0.05, and an absolute fold change of <0.77 (down-regulation) or >1.3 (up-regulation) in 194 
linear scale were considered significantly differentially expressed.  195 
2.5 Bioinformatics 196 
 The proteomic data were analyzed using STRING (56) and QIAGEN’s Ingenuity® 197 
Pathway Analysis (IPA) (QIAGEN Redwood City, www.qiagen.com/ingenuity), to 198 
detect and infer differentially activated/deactivated pathways because of Delta-24RGD 199 
treatment. STRING database includes interactions from published literature describing 200 
experimentally studied interactions, as well as those from genome analysis using several 201 
well-established methods based on domain fusion, phylogenetic profiling and gene 202 
neighbourhood concepts. Accordingly, a confidence score for every protein–protein 203 
association was assigned to the network. A higher score was assigned when an association 204 
is supported by several types of evidence. To minimize false positives as well as false 205 
negatives, all interactions tagged as “low-confidence” (<0.4) in STRING database have 206 
been eliminated from this study. IPA software comprises curated information from 207 
databases of experimental and predictive origin, enabling discovery of highly represented 208 
functions, pathways, and interactome networks. The IPA comparison analysis considers 209 
the signalling pathway rank according to the calculated p-value and reports it 210 
hierarchically. The software generates significance values (p-values) between each 211 
biological or molecular event and the imported molecules based on the Fisher ́s exact test 212 
(p ≤ 0.05). 213 
2.6 Protein arrays 214 
For the secretome analysis, a dot-blot protein array was used for cytokine profiling 215 
(Abcam). Briefly, membranes with 80 cytokine antibodies were blocked with the 216 
manufacturer's blocking buffer at room temperature (RT) for 30 min, and incubated o/n 217 
with 1ml of undiluted cell-cultured media from Mock- and U87-infected cells (24, 48hpi) 218 
(n=3). After washing, a biotinylated anti-cytokine antibody mixture was added to the 219 
membranes followed by incubation with HRP-conjugated streptavidin and then exposed 220 
to the manufacturer's peroxidase substrate. For phospho-kinome analysis, the Proteome 221 
Profiler Array (R&D Systems. Ref: 894552) was used according to the manufacturer 222 
instructions. Cell lysates derived from Mock- and U87-infected cells (5, 15, 30 mpi) (n=3) 223 
were diluted and incubated overnight with the Human Phospho-Kinase Array, that 224 
contains 43 different capture antibodies printed in duplicate. The arrays were washed to 225 
remove unbound proteins followed by incubation with a cocktail of biotinylated detection 226 
antibodies. Streptavidin-HRP and chemiluminescent detection reagents were applied and 227 
a signal was produced at each capture spot corresponding to the amount of 228 
phosphorylated protein bound. For both protein array platforms, chemiluminescence 229 
signals were quantified with the ImageQuant ECL system (BioRad) and normalized to 230 
the positive control signals. The Perseus software (version 1.5.6.0) was used for statistical 231 
analysis (57). 232 
2.7 Western-blotting 233 
Equal amounts of protein (10 μg) were resolved in 4–15% Criterion™ TGX Stain-Free™ 234 
Protein Gels (#5678085 Bio-rad). Mock-infected and U87-infected protein cell extracts 235 
were electrophoretically transferred onto nitrocellulose membranes using Trans-Blot 236 
Turbo (BioRad) for 7 minutes at 2.5A constant, up to 25V. Equal loading of the gels was 237 
assessed by stain free digitalization and Ponceau staining. Membranes were probed with 238 
primary antibodies at 1:1000 dilution in 5% nonfat milk or BSA. After incubation with 239 
the appropriate horseradish peroxidase-conjugated secondary antibody (1:5000), 240 
antibody binding was detected by a ChemidocMP Imaging System (Bio-Rad) after 241 
incubation with an enhanced chemiluminescence substrate (Perkin Elmer). All Band 242 
intensities were measured with Image Lab Software Version 5.2 (Bio-Rad), and 243 
normalized to GAPDH or to total stain in each gel lane (58). 244 
3. Results and discussion 245 
Glioblastoma multiforme (GBM) is the most aggressive type of malignant glioma, 246 
characterized by infiltrative growth causing progressive neurologic dysfunction (14). One 247 
of the treatment strategies currently used is the oncolytic virotherapy (15, 16), that 248 
combines tumoral cell lysis with systemic anti-tumor immunity induction. Delta-24-249 
RGD, also known as DNX-2401, is currently under investigation in clinical trials for 250 
GBM (8). However, the global molecular events that accompany the adenoviral infective 251 
process remain to be elucidated. We consider that a system-wide characterization of 252 
initial phosphoproteomic events as well as the intracellular and extracellular glioma 253 
proteomes underlying the regulation of autophagy upon Delta-24-RGD infection (Figure 254 
1) may provide new inducing or inhibiting strategies to improve the therapeutic effect 255 
against target glioma cells. 256 
3.1 Delta-24-RGD-receptor interactions rapidly modulate the glioma phosphoproteome 257 
To identify signaling events induced soon after Delta-24-RGD engagement of cell surface 258 
receptors, phospho-kinase arrays were performed at 5, 15, and 30 minutes post-infection 259 
(mpi). To synchronize virus binding, we added a high concentration of virus (MOI=25) 260 
in order to obtain a sufficient number of binding events within a very short time-frame. 261 
As shown in figure 2, a time-dependent dephosphorylation of specific survival routes was 262 
observed (Akt, GSK-3, ERK1/2, p38 MAPK, MSK1/2 between others), indicating that 263 
Delta-24-RGD induces an early survival reprogramming of glioma cells for an optimal 264 
viral replication. Akt was progressively inactivated during the time-points analysed 265 
(Figure 2A-B). Phospho-WNK-1 (T60), an Akt substrate implicated in regulating ion 266 
permeability (17, 18) was also dephosphorylated during the first 30 mpi (Figure 2A-B). 267 
Interestingly, the activation of WNK-1/OSR1/NKCC1 signaling pathway facilitates 268 
glioma cell migration and apoptotic resistance to the chemotherapeutic drug 269 
temozolomide (TMZ) (19), reinforcing the idea that co-treatment of glioma cells with 270 
TMZ and Delta-24-RGD might lead to an enhanced therapeutic effect (20). c-Jun was the 271 
unique factor that rapidly increased its activator phosphorylation (Figure 2A-B). 272 
Although Jun N-terminal kinases (JNKs) are the canonical regulator of c-Jun activity (21, 273 
22), a JNK activation was not observed at 5-15 mpi (Figure 2C-D), indicating that 274 
additional kinases (23) may be responsible for the c-Jun early activation peak during 275 
Delta-24-RGD attachment. Together with the shut off induced in the kinase-mediated 276 
signaling, several transcription factors were rapidly inhibited (30mpi) such as STAT2 and 277 
STAT5b (figure 2C-D), probably blocking the antiviral defense (24), causing cycle arrest, 278 
and inhibiting glioma cell growth (25). 279 
3.2 Delta-24-RGD induces protein interactome derangements late in infection  280 
It is well known that for an efficient cell lysis and adenoviral spread, Delta-24-RGD 281 
induces massive autophagy (10-12). We have determined the Delta-24-RGD-induced 282 
glioma proteome remodelling that occurs in parallel with the overproduction viral 283 
proteins and the concomitant activation of Akt and c-Jun at 48hpi (9) (Figure 3A). Among 284 
the 1616 intracellular proteins consistently quantified (figure 3B and supplementary table 285 
1), 240 proteins tend to be differentially expressed between Mock and glioma-infected 286 
cells (127 up-regulated, and 113 down-regulated proteins) (figure 3B and Supplementary 287 
table 2), being potentially distributed across nuclear, cytosolic, exosome, and membranes 288 
between other organelles (Figure 3C). In addition, the over-production of 18 adenoviral 289 
proteins was also detected by mass-spectrometry (supplementary table 2). In accordance 290 
with previous studies (9, 26), Delta-24-RGD modulates proteomic fingerprints involved 291 
in EIF2 and mTOR signalling (figure 3D). Changes in the expression of various 292 
autophagy-related biomarker proteins were also detected in our proteomic survey. p62 293 
(SQSTM1) down-regulation was evidenced in Delta-24-RGD-infected glioma cells. This 294 
molecular event is a marker of autophagy in oncolytic adenovirus-infected tumor cells, 295 
where p62 may act as a receptor for ubiquitinated proteins or organelles (27), being finally 296 
degraded by the autolysosome (28). The autophagosome-lysosome fusion requires the 297 
lysosomal membrane protein LAMP-2 (27), an over-expressed protein in Delta-24-RGD-298 
infected cells. Moreover, cytoskeleton organization (RhoA signaling, ILK signaling), 299 
inflammation (IL-8 signaling), oxidative response, and differentiation (Tec kinase 300 
signalling, HGF and integrin signalling) were disrupted biological functions that 301 
accompanied Delta-24-RGD-mediated autophagy (figure 3D). Interestingly, deregulated 302 
proteins involved in protein synthesis (Ribosome biogenesis protein BOP1, 60S acidic 303 
ribosomal protein P2, 40S ribosomal protein S23) and DNA/RNA metabolism (TATA-304 
binding protein-associated factor 2N, DNA-directed RNA polymerases I and III subunit 305 
RPAC1, DNA replication licensing factor MCM4, Cleavage stimulation factor subunit 3, 306 
and RNA-binding protein FUS) at 48 hpi, have been previously proposed as Delta-24-307 
RGD targets early in infection (26). To characterize in detail the glioma proteotype upon 308 
Delta-24-RGD infection in the autophagic stage, we have performed proteome-scale 309 
interaction networks merging the 240 differential proteins detected in glioma-infected 310 
cells (48 hpi) (Figure 4). The protein interactome was mainly composed by specific 311 
protein clusters related to Poly(A) RNA binding, translation, mRNA splicing, and AMP 312 
metabolism. As shown in figure 4, Delta-24-RGD treatment directly affects the protein 313 
tyrosine kinase signalling, highly associated with glioblastoma oncogenesis (29).  314 
3.3 Activation state of predictive interactome hubs upon Delta-24-RGD infection 315 
We have applied a system biology approach to establish a framework to monitor 316 
interaction between deregulated proteins and potential network modules that may be 317 
considered as protein targets to modulate the infectivity process. Akt and JNK appeared 318 
as functional interactors of part of the deregulated proteome (supplementary file 3), being 319 
activated during Delta-24-RGD mediated autophagy (9). As shown in figure 5, NFκB 320 
also appeared as a hub in the differential interactome network. Subsequent experiments 321 
were performed to monitor the activation state of this signal transducer late in infection 322 
(Figure 5A). The increment in the serine 536 pohosphorylation of NFκB (24-48hpi) and 323 
the drop in the levels of the NFκB inhibitor alpha (IκB-alpha) at 48hpi suggests a potential 324 
activation of this transcription factor. Previous studies point out that adenovirus infection 325 
induces the activation of NF-κB in cancer cell lines (30, 31), being associated with 326 
resistance to different cell death and chemotherapeutic strategies in GBM (32), 327 
suggesting that Delta-24-RGD-induced NF-κB activation might be a protection 328 
mechanism induced by glioma cells. PKC isozymes are overexpressed in astroglial brain 329 
tumors (33). Our data indicate that Delta-24-RGD decreases PKC protein levels (Figure 330 
5B), probably restraining the hyperproliferative state and the invasive capacity of 331 
malignant glioma cells (34). Despite src kinase is also frequently activated in GBM, the 332 
use of specific inhibitory strategies has demonstrated a reduction in cell viability, and 333 
migration (35) as well as an induction of autophagic cell death in GBM cells (36). As 334 
shown in figure 5B, the essential phosphorylation of Y419 in the activation loop of c-src 335 
(37), and total c-src levels were markedly reduced in glioma-infected cells at 48hpi 336 
(Figure 5B). Moreover, Delta-24-RGD also affects the MAPK pathway, as suggested by 337 
the down-regulation of ERK (Supplementary table 2) and its target MEK1/2 (figure 6A). 338 
All these data point out that Delta-24-RGD treatment directly interferes with signaling 339 
pathways involved in cell growth, proliferation, adhesion, and migration. Due to the 340 
reduction of PKA type 1a regulatory subunit (PRKAR1A) in Delta-24-RGD-infected 341 
cells (Supplementary Table 2, network figure 6A), we focus our attention in the potential 342 
deregulation of PKA activation. As shown in figure 6A, an increment in phosphorylated 343 
and total PKA levels was evidenced at 24hpi. Being PKA an E1A adenoviral protein 344 
interactor, the co-overexpression of both proteins observed at 24hpi may contribute to 345 
viral transcription, protein expression and progeny production (38). However, PKA 346 
activation was reduced at 48hpi (figure 6A). This PKA inhibition was supported by the 347 
down-regulation of Ras GTPase-activating protein 1 (RASA1), an inhibitory regulator of 348 
the Ras-cyclic AMP pathway, that compromises cAMP generation.  349 
A growing body of evidences indicates that total and phosphorylated GSK-3 levels are 350 
increased in GBM, influencing its malignant phenotype (39). As shown in figure 6A, a 351 
dephosphorylation of GSK3/ was observed at 24hpi, while GSK3/ protein levels 352 
tend to be reduced at 48hpi. Although targeting of PKA and GSK-3 activity may result 353 
in glioma conventional cell death (40-42), PKA inhibition and GSK-3 down-regulation 354 
could also contribute to Delta-24-RGD-induced autophagic flux in glioma cells (27, 43). 355 
On the other hand, Delta-24-RGD also targeted serine/threonine protein phosphatase 356 
homeostasis in glioma cells late in infection. Specifically, Delta-24-RGD induced the 357 
overproduction of serine/threonine-protein phosphatase 6 catalytic subunit (PPP6C), PP4 358 
regulatory subunit 3A (PPP4R3A) and PP1-beta catalytic subunit (PPP1CB) 359 
(Supplementary table 2). All of them have been previously related to glioblastoma 360 
invasion and recurrence (44). Figure 6B shows the PP1/PP2A-regulated interactome 361 
modulated by Delta-24-RGD. Despite the slight PP1- α catalytic subunit activation (by 362 
dephosphorylation) observed at 24hpi in infected-glioma cells, Delta-24-RGD induced a 363 
decrease in PP1α subunit and PP2A α/β catalytic subunit protein levels at 48hpi (figure 364 
6B). Both S/T phosphatases are adenoviral E4orf4 protein interactors (45, 46) and 365 
cooperating partners in modulating the mitotic progression and tumor growth (47, 48), 366 
although a duality in the GBM field exists because PP2A inhibition or activation appear 367 
to be anti-oncogenic (44). Other protein that takes part in the PP1/PP2A-regulated 368 
interactome, is calreticulin (CALR), which expression is induced during Delta-24-RGD 369 
infection (figure 6B, and supplementary table 2). Interestingly, this protein is a damage-370 
associated molecular pattern (DAMP) molecule involved in the induction of antitumor 371 
immune response during antitumor therapy-induced autophagy (49, 50). 372 
 373 
 374 
3.4 Delta-24-RGD triggers changes in the glioma secretome late in infection 375 
Based on cerebrospinal fluid analysis derived from GBM patients, Delta-24-RGD therapy 376 
alters the tumor microenvironment (51). Considering that the monitorization of cytokines 377 
and growth factors specifically secreted by glioma cells to the tumor microenvironment 378 
may provide new insights into the modulation of the immune response induced by Delta-379 
24-RGD, we have performed a complementary secretome analysis of infected-glioma 380 
cells at 24 and 48hpi. Among the 80 secreted cell–cell signaling molecules analyzed, 14 381 
were significantly increased in a time-dependent manner (Figure 7A). TGF-beta3 was 382 
significantly increased at 24 hpi whereas the chemotactic factor GRO (CXCL1), TIMP-383 
1, and TIMP-2 were up-regulated at 24-48 hpi. Other cytoquines such as GM-CSF, IL-8 384 
(CXCL8), angiogenin, BLC (CXCL13), HGF, IGFBP-1, MIF, osteopontin, and 385 
osteoprotegerin (TNFRSF11B) were specifically overproduced at 48 hpi (Figure 7A). 386 
Some of this cytokine and growth factors (GM-CSF, CXCL1, CXCL8, TIMP-1, TIMP-387 
2, TNFRSF11B) are targets of the NFκB complex. These data indicated that the cytokine 388 
secretion waves induced by Delta-24-RGD are highly dynamic and time-dependent 389 
during all phases of Delta-24-RGD viral cycle (26). To explore the cooperative action 390 
among differentially intracellular and extracellular molecules induced by Delta-24-RGD 391 
at 48hpi, we have performed additional pathway analysis merging the proteomic dataset 392 
and the secretome information. As shown in figure 7B, Delta-24-RGD modulates 393 
pathways related to accumulation, migration, and activation of different inflammatory 394 
cells late in infection (supplementary table 4). It has been previously reported that Delta-395 
24-RGD induces a prolonged shift in the pro-tumoral M2 macrophages towards tumor-396 
detrimental phenotype as well as leukocyte recruitment and activation in GBM patients 397 
(51). All these data complement the notion that the immune system plays a fundamental 398 
role in the therapeutic efficacy of oncolytic Delta-24-RGD therapy of glioma (52-54).   399 
4. Conclusion 400 
This work provides new insights regarding the molecular mechanisms governing the 401 
glioma metabolism during Delta-24-RGD oncolytic adenoviral therapy. Although 402 
additional experiments are needed to evaluate the effect of Delta-24-RGD in additional 403 
cell lines and in vivo models, the application of high-throughput proteomic approaches 404 
proves to be a useful tool to decipher the proteome expression profiles of glioma cells 405 
during antitumor therapy, and more importantly, to define potential therapeutic targets 406 
against GBM.  407 
 408 
Figure legends 409 
Figure 1. Spatio-temporal multi-omic approach applied throughout Delta-24-RGD 410 
Infection.  411 
Figure 2. Rapid phospho-kinome response of Delta-24-RGD-infected cells during 412 
the first 30 minutes of infection. Phosphoproteome variations detected at 5, 15, and 30 413 
mpi respect to mock-infected cells (A, C). Representative images of phospho-kinase 414 
arrays are shown (B, D). 415 
Figure 3. Differentially expressed proteins throughout late phases of Delta-24-RGD 416 
Infection. A) Expression of adenoviral proteins in glioma-infected cells. B) Volcano plot 417 
representing the fold-change of identified proteins with associated P values from the pair-418 
wise quantitative comparison of mock vs glioma-infected proteome at 48hpi (Left). In 419 
green, significantly down-regulated proteins, and in red, upregulated proteins (P < 0.05). 420 
(C) Subcellular and (D) pathway distribution of the glioma proteome modulated by Delta-421 
24-RGD (48hpi). 422 
Figure 4. Protein interactome network for Delta-24-RGD-modulated proteome. 423 
Network analysis was performed submitting the corresponding protein IDs to the 424 
STRING (Search Tool for the Retrieval of Interacting Genes) software (v.10.5) 425 
(http://stringdb.org/). Proteins are represented with nodes and the interactions with 426 
continuous lines to represent direct interactions (physical), while indirect ones 427 
(functional) are presented by interrupted lines. All the edges were supported by at least a 428 
reference from the literature or from canonical information stored in the STRING 429 
database. To minimize false positives as well as false negatives, only interactions tagged 430 
as “high confidence” (>0.7) in STRING database were considered. K means clustering 431 
was applied. 432 
Figure 5. Delta-24-RGD-modulated proteome is functionally related with NFκB, 433 
SRC, and PKC. Specific protein interactomes modulated by Delta-24-RGD in glioma 434 
cells late in infection (48hpi) (down- and up-regulated proteins in Delta-24-RGD-infected 435 
glioma cells in green and red respectively). Levels and residue-specific phosphorylation 436 
of NFκB and IκB (A), PKC, and c-SRC (B) at 24-48hpi. Equal loading of the gels was 437 
assessed by Ponceau staining and band intensities were normalized to total stain in each 438 
gel lane. Representative Western blot images from three independent experiments are 439 
shown. 440 
Figure 6. Delta-24-RGD induces specific signaling derangements late in infection. 441 
Specific kinase-regulated interactomes modulated by Delta-24-RGD in glioma cells at 442 
48hpi (down- and up-regulated proteins in Delta-24-RGD-infected glioma cells in green 443 
and red respectively). Levels and residue-specific phosphorylation of PKAc, MEK1/2, 444 
and GSK3- / (B) at 24-48hpi. Equal loading of the gels 445 
was assessed by Ponceau staining and band intensities were normalized to total stain in 446 
each gel lane. Representative Western blot images from three independent experiments 447 
are shown. 448 
Figure 7. Delta 24-RGD induces late changes in the extracellular cytokine profiling 449 
of glioma cells. A time-dependent analysis of 80 cytokines/growth factors was performed 450 
in the cell media of mock-infected glioma cells and glioma-infected cells (24, and 48hpi) 451 
using a dot-blot protein array method. Three independent experiments were performed. 452 
Data are presented as mean ± SEM. *p < 0.05, **p<0.01, and ***p<0.001 vs mock-453 
infected condition (A). Pathway mapping of intracellular deregulated proteins and the 454 
differential secretome obtained by IPA software (supplementary table 4) (B). 455 
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